Growth investors are always searching for companies where the business itself is compounding, and the market is only just starting to price that in. This week, a screen designed to find exactly that dynamic, strong growth fundamentals paired with a technical breakout setup, flagged Corcept Therapeutics Inc (NASDAQ:CORT). The idea behind this approach is simple: you want a stock where the underlying financials are expanding (revenue, earnings, margins) and the chart is confirming that trend by breaking out of a range or reaching new highs. When both line up, the probability of a sustained move increases significantly.
Recent Performance
Corcept Therapeutics has been one of the stronger performers in the Pharmaceuticals industry over the past year. The stock is currently trading near its 52-week high of $95.11, having delivered a 12-month return of roughly 28%. Drilling into the short-term picture, the momentum is even more striking: the stock has gained 17.6% in the last month alone, and an eye-catching 145% over the past six months. For context, the S&P 500’s long-term and short-term trends are both positive, but CORT has meaningfully outperformed the broader market.
Volume has been solid, averaging about 1.14 million shares per day over the last 50 days, which provides the liquidity growth investors need to enter and exit positions without excessive slippage.
Fundamental Strength
The fundamental analysis report gives Corcept an overall rating of 6 out of 10, but the more important story lies in the sub-scores. The stock earned a Growth rating of 7 out of 10, driven by two key factors that matter most for growth investors.
First, revenue growth remains strong. The company posted 12.2% year-over-year revenue growth in the last twelve months, and the five-year average is a healthy 16.56%. More importantly, analysts expect revenue to accelerate to 26.75% average growth over the next few years. Second, while the last year’s earnings per share (EPS) declined sharply (down 69.83%), the forward-looking picture is dramatically different. Analysts project EPS will grow by an average of 76.37% per year over the next several years. That kind of expected acceleration, where growth is actually speeding up, is exactly what the growth investing method looks for.
The Health rating is 8 out of 10, which is excellent. Corcept carries zero debt on its balance sheet, meaning its expansion is funded by operations rather than leverage. The Altman-Z score of 36.32 signals virtually no bankruptcy risk. For growth investors, low debt is critical because it means the company won’t be squeezed if interest rates stay elevated or if the macro environment tightens.
Profitability came in at a 6 out of 10. Margins are strong, gross margins are 98.25%, which is best-in-class, but operating and profit margins have slipped recently. Still, with a Return on Equity of 7.42% and a Return on Assets of 5.81%, both better than 82% of industry peers, the company remains solidly profitable.
The valuation score of 4 out of 10 reflects a high trailing P/E of 262.51, which is typical for a growth name with a steep earnings ramp ahead. The forward P/E of 42.89 is far more reasonable, and the expected EPS growth of 83.66% in the coming year helps justify the multiple. This is a classic growth-at-a-reasonable-price scenario: you pay up now for the expansion that is already underway.
Technical Setup
The technical analysis report rates Corcept a 9 out of 10, with a Setup Rating of 7 out of 10. This indicates the stock has excellent trend characteristics but is currently in a somewhat volatile zone, meaning traders may want to wait for a brief consolidation before entering.
The short-term, medium-term, and long-term trends are all positive. The stock is trading above its 20-day, 50-day, 100-day, and 200-day simple moving averages, and all four are rising. That's textbook bullish alignment. Corcept also outperforms 85% of stocks in the Pharmaceuticals industry on relative strength.
The setup itself suggests a potential entry near $95.12, using a buy stop order just above the 10-day high, with a stop loss near $88.79. The worst-case loss on that trade would be about 6.65%, which is within a reasonable risk range for a growth trade. The nearest support is at $88.80 from a daily trend line, with a deeper support zone around $79.80.
When compared to the growth strategy outlined in the introduction, Corcept checks every box: strong and accelerating revenue and earnings growth, a rock-solid balance sheet, and a chart that is trending positively with a potential breakout setup. The combination of high relative strength and low debt makes it a textbook candidate for a growth investor looking for a stock that is both fundamentally sound and technically poised.
Screen Results
This stock was identified using a 'Strong Growth Stocks with good Technical Setup Ratings' screen, which filters for companies with high ChartMill Growth ratings (7 or better), decent Health and Profitability scores, strong relative strength, and clear technical breakout patterns. You can run the same screen to find additional candidates by visiting the ChartMill Screener and exploring the current results.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Always conduct your own research and consider your risk tolerance before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup
Growth investors are always searching for companies where the business itself is compounding, and the market is only just starting to price that in. This week, a screen designed to find exactly that dynamic, strong growth fundamentals paired with a technical breakout setup, flagged Corcept Therapeutics Inc (NASDAQ:CORT). The idea behind this approach is simple: you want a stock where the underlying financials are expanding (revenue, earnings, margins) and the chart is confirming that trend by breaking out of a range or reaching new highs. When both line up, the probability of a sustained move increases significantly.
Recent Performance
Corcept Therapeutics has been one of the stronger performers in the Pharmaceuticals industry over the past year. The stock is currently trading near its 52-week high of $95.11, having delivered a 12-month return of roughly 28%. Drilling into the short-term picture, the momentum is even more striking: the stock has gained 17.6% in the last month alone, and an eye-catching 145% over the past six months. For context, the S&P 500’s long-term and short-term trends are both positive, but CORT has meaningfully outperformed the broader market.
Volume has been solid, averaging about 1.14 million shares per day over the last 50 days, which provides the liquidity growth investors need to enter and exit positions without excessive slippage.
Fundamental Strength
The fundamental analysis report gives Corcept an overall rating of 6 out of 10, but the more important story lies in the sub-scores. The stock earned a Growth rating of 7 out of 10, driven by two key factors that matter most for growth investors.
First, revenue growth remains strong. The company posted 12.2% year-over-year revenue growth in the last twelve months, and the five-year average is a healthy 16.56%. More importantly, analysts expect revenue to accelerate to 26.75% average growth over the next few years. Second, while the last year’s earnings per share (EPS) declined sharply (down 69.83%), the forward-looking picture is dramatically different. Analysts project EPS will grow by an average of 76.37% per year over the next several years. That kind of expected acceleration, where growth is actually speeding up, is exactly what the growth investing method looks for.
The Health rating is 8 out of 10, which is excellent. Corcept carries zero debt on its balance sheet, meaning its expansion is funded by operations rather than leverage. The Altman-Z score of 36.32 signals virtually no bankruptcy risk. For growth investors, low debt is critical because it means the company won’t be squeezed if interest rates stay elevated or if the macro environment tightens.
Profitability came in at a 6 out of 10. Margins are strong, gross margins are 98.25%, which is best-in-class, but operating and profit margins have slipped recently. Still, with a Return on Equity of 7.42% and a Return on Assets of 5.81%, both better than 82% of industry peers, the company remains solidly profitable.
The valuation score of 4 out of 10 reflects a high trailing P/E of 262.51, which is typical for a growth name with a steep earnings ramp ahead. The forward P/E of 42.89 is far more reasonable, and the expected EPS growth of 83.66% in the coming year helps justify the multiple. This is a classic growth-at-a-reasonable-price scenario: you pay up now for the expansion that is already underway.
Technical Setup
The technical analysis report rates Corcept a 9 out of 10, with a Setup Rating of 7 out of 10. This indicates the stock has excellent trend characteristics but is currently in a somewhat volatile zone, meaning traders may want to wait for a brief consolidation before entering.
The short-term, medium-term, and long-term trends are all positive. The stock is trading above its 20-day, 50-day, 100-day, and 200-day simple moving averages, and all four are rising. That's textbook bullish alignment. Corcept also outperforms 85% of stocks in the Pharmaceuticals industry on relative strength.
The setup itself suggests a potential entry near $95.12, using a buy stop order just above the 10-day high, with a stop loss near $88.79. The worst-case loss on that trade would be about 6.65%, which is within a reasonable risk range for a growth trade. The nearest support is at $88.80 from a daily trend line, with a deeper support zone around $79.80.
When compared to the growth strategy outlined in the introduction, Corcept checks every box: strong and accelerating revenue and earnings growth, a rock-solid balance sheet, and a chart that is trending positively with a potential breakout setup. The combination of high relative strength and low debt makes it a textbook candidate for a growth investor looking for a stock that is both fundamentally sound and technically poised.
Screen Results
This stock was identified using a 'Strong Growth Stocks with good Technical Setup Ratings' screen, which filters for companies with high ChartMill Growth ratings (7 or better), decent Health and Profitability scores, strong relative strength, and clear technical breakout patterns. You can run the same screen to find additional candidates by visiting the ChartMill Screener and exploring the current results.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Always conduct your own research and consider your risk tolerance before making any investment decisions.
Read full article here »